Targeting peptide antigens using a multiallelic MHC I-binding system

Identifying highly specific T cell receptors (TCRs) or antibodies against epitopic peptides presented by class I major histocompatibility complex (MHC I) proteins remains a bottleneck in the development of targeted therapeutics. Here, we introduce targeted recognition of antigen-MHC complex reporter for MHC I (TRACeR-I), a generalizable platform for targeting peptides on polymorphic HLA-A*, HLA-B* and HLA-C* allotypes while overcoming the cross-reactivity challenges of TCRs. Our TRACeR-MHC I co-crystal structure reveals a unique antigen recognition mechanism, with TRACeR forming extensive contacts across the entire peptide length to confer single-residue specificity at the accessible positions. We demonstrate rapid screening of TRACeR-I against a panel of disease-relevant HLAs with peptides derived from human viruses (human immunodeficiency virus, Epstein-Barr virus and severe acute respiratory syndrome coronavirus 2), and oncoproteins (Kirsten rat sarcoma virus, paired-like homeobox 2b and New York esophageal squamous cell carcinoma 1). TRACeR-based bispecific T cell engagers and chimeric antigen receptor T cells exhibit on-target killing of tumor cells with high efficacy in the low nanomolar range. Our platform empowers the development of broadly applicable MHC I-targeting molecules for research, diagnostic and therapeutic applications.

Authors

Institutions

Publication Details

Journal
Nature Biotechnology
Published
2024-12-13
DOI
https://doi.org/10.1038/s41587-024-02505-8
Citations
21
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
5.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeting peptide antigens using a multiallelic MHC I-binding system

Stephen D. Carro, Reem Ghinnagow, Hoang Anh T. Phan, Chengzi I. Kaku et al.
21 citations
Nature Biotechnology
Immunotherapy and Immune Responses
5.05
article

Targeting peptide antigens using a multiallelic MHC I-binding system

Stephen D. Carro, Reem Ghinnagow, Hoang Anh T. Phan, Chengzi I. Kaku, Daniel Hoces, Po‐Ssu Huang, Hyejin Lee, Haotian Du, Nikolaos G. Sgourakis, Emily Zhou, Joseph G. Jardine, Gina El Nesr, Jingjia Liu, Daniel Hwang, Laurence C. Eisenlohr, Leena Mallik, Wyatt Blackson, Christian A. Choe, Kimia Dasteh Goli, Devin Dersh, Yi Sun, Georgia Papadaki, Rogelio A. Hernández‐López, Andy J. Minn, Michael C. Young, Sagar Gupta, Hongli Yang, Shirley M. Sun, Braxton Bell
article en
21 citations

Abstract

Identifying highly specific T cell receptors (TCRs) or antibodies against epitopic peptides presented by class I major histocompatibility complex (MHC I) proteins remains a bottleneck in the development of targeted therapeutics. Here, we introduce targeted recognition of antigen-MHC complex reporter for MHC I (TRACeR-I), a generalizable platform for targeting peptides on polymorphic HLA-A*, HLA-B* and HLA-C* allotypes while overcoming the cross-reactivity challenges of TCRs. Our TRACeR-MHC I co-crystal structure reveals a unique antigen recognition mechanism, with TRACeR forming extensive contacts across the entire peptide length to confer single-residue specificity at the accessible positions. We demonstrate rapid screening of TRACeR-I against a panel of disease-relevant HLAs with peptides derived from human viruses (human immunodeficiency virus, Epstein-Barr virus and severe acute respiratory syndrome coronavirus 2), and oncoproteins (Kirsten rat sarcoma virus, paired-like homeobox 2b and New York esophageal squamous cell carcinoma 1). TRACeR-based bispecific T cell engagers and chimeric antigen receptor T cells exhibit on-target killing of tumor cells with high efficacy in the low nanomolar range. Our platform empowers the development of broadly applicable MHC I-targeting molecules for research, diagnostic and therapeutic applications.

Nature BiotechnologyVol. 43(10)
Scripps Research Institute (US), Children's Hospital of Philadelphia (US), Chan Zuckerberg Initiative (United States) (US), University of Pennsylvania (US), Stanford University (US)
National Science Foundation, U.S. Department of Energy, American Cancer Society, Stanford University, Children's Hospital of Philadelphia, Mark Foundation For Cancer Research, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, National Institutes of Health, Office of Science, School of Medicine, Stanford University, University of California, San Francisco, Stanford Bio-X, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, Biological and Environmental Research
Openalex Percentile: Top 4%
Immunotherapy and Immune Responses
5.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.